Drug Trial Radar · NCT05515536
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
Last checked: Nov 20, 2026Latest source record: Oct 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
130
Actual
Start
Dec 8, 2022
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- PTC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.
Conditions
- Friedreich Ataxia
Interventions
VatiquinoneDrug
Vatiquinone will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Baseline up to 3 years
Locations
14 sites in 9 countries. Site status is shown where the registry gives one.
UCLA
Los Angeles, California
University of Florida
Gainesville, Florida
University of South Florida
Tampa, Florida
University of Iowa
Iowa City, Iowa
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Murdoch Children's Research Institute
Parkville, Victoria, Australia
University of Campinas (UNICAMP) - School of Medical Sciences, Dept of Neurology
São Paulo, Brazil
Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM)
Montreal, Quebec, Canada
CHU Sainte-Justine
Montreal, Quebec, Canada
Hôpital Pitié-Salpêtrière, Institut du Cerveau (Paris Brain Institute)
Paris, France
Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE)
Tübingen, Germany
Ospedale Pediatrico Bambino Gesu' IRCCS
Roma, Italy
CBR Neurogenetic Research Clinic, University of Auckland
Auckland, New Zealand
Hospital Sant Joan de Déu Barcelona Unidad de Enfermedades Neuromusculares
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.